checkAd

     133  0 Kommentare Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures - Seite 2

    CONTACTS:

    Jack A. Khattar, President and CEO
    Timothy C. Dec, Senior Vice President and CFO
    Supernus Pharmaceuticals, Inc.
    Tel: (301) 838-2591

    or

    Lesen Sie auch

    INVESTOR CONTACT:
    Peter Vozzo
    ICR Westwicke
    Office: (443) 213-0505
    Email: peter.vozzo@westwicke.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 2 von 2

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures - Seite 2 ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) - Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today …